314 related articles for article (PubMed ID: 17535101)
1. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza.
Simmons CP; Bernasconi NL; Suguitan AL; Mills K; Ward JM; Chau NV; Hien TT; Sallusto F; Ha do Q; Farrar J; de Jong MD; Lanzavecchia A; Subbarao K
PLoS Med; 2007 May; 4(5):e178. PubMed ID: 17535101
[TBL] [Abstract][Full Text] [Related]
2. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.
Zanin M; Keck ZY; Rainey GJ; Lam CY; Boon AC; Rubrum A; Darnell D; Wong SS; Griffin Y; Xia J; Webster RG; Webby R; Johnson S; Foung S
J Virol; 2015 Apr; 89(8):4549-61. PubMed ID: 25673719
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza.
Prabhu N; Prabakaran M; Hongliang Q; He F; Ho HT; Qiang J; Goutama M; Lim AP; Hanson BJ; Kwang J
Antivir Ther; 2009; 14(7):911-21. PubMed ID: 19918095
[TBL] [Abstract][Full Text] [Related]
4. Development of monoclonal antibodies to highly pathogenic avian influenza H5N1 virus and their application to diagnostics, prophylaxis, and therapy.
Masalova OV; Klimova RR; Chichev EV; Fediakina IT; Loginova SY; Borisevich SV; Bondarev VP; Deryabin PG; Lvov DK; Kushch AA
Acta Virol; 2011; 55(1):3-14. PubMed ID: 21434700
[TBL] [Abstract][Full Text] [Related]
5. Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection.
Itoh Y; Yoshida R; Shichinohe S; Higuchi M; Ishigaki H; Nakayama M; Pham VL; Ishida H; Kitano M; Arikata M; Kitagawa N; Mitsuishi Y; Ogasawara K; Tsuchiya H; Hiono T; Okamatsu M; Sakoda Y; Kida H; Ito M; Quynh Mai L; Kawaoka Y; Miyamoto H; Ishijima M; Igarashi M; Suzuki Y; Takada A
PLoS Pathog; 2014 Jun; 10(6):e1004192. PubMed ID: 24945244
[TBL] [Abstract][Full Text] [Related]
6. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
Throsby M; van den Brink E; Jongeneelen M; Poon LL; Alard P; Cornelissen L; Bakker A; Cox F; van Deventer E; Guan Y; Cinatl J; ter Meulen J; Lasters I; Carsetti R; Peiris M; de Kruif J; Goudsmit J
PLoS One; 2008; 3(12):e3942. PubMed ID: 19079604
[TBL] [Abstract][Full Text] [Related]
7. A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms.
Tan Y; Ng Q; Jia Q; Kwang J; He F
J Virol; 2015 Apr; 89(7):3712-22. PubMed ID: 25609802
[TBL] [Abstract][Full Text] [Related]
8. Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.
Nachbagauer R; Shore D; Yang H; Johnson SK; Gabbard JD; Tompkins SM; Wrammert J; Wilson PC; Stevens J; Ahmed R; Krammer F; Ellebedy AH
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899095
[TBL] [Abstract][Full Text] [Related]
9. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice.
Hanson BJ; Boon AC; Lim AP; Webb A; Ooi EE; Webby RJ
Respir Res; 2006 Oct; 7(1):126. PubMed ID: 17040574
[TBL] [Abstract][Full Text] [Related]
10. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
[TBL] [Abstract][Full Text] [Related]
11. Selection of therapeutic H5N1 monoclonal antibodies following IgVH repertoire analysis in mice.
Gray SA; Moore M; VandenEkart EJ; Roque RP; Bowen RA; Van Hoeven N; Wiley SR; Clegg CH
Antiviral Res; 2016 Jul; 131():100-8. PubMed ID: 27109194
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants.
Prabakaran M; Prabhu N; He F; Hongliang Q; Ho HT; Qiang J; Meng T; Goutama M; Kwang J
PLoS One; 2009 May; 4(5):e5672. PubMed ID: 19478856
[TBL] [Abstract][Full Text] [Related]
13. Cross-protective potential of anti-nucleoprotein human monoclonal antibodies against lethal influenza A virus infection.
Fujimoto Y; Tomioka Y; Takakuwa H; Uechi GI; Yabuta T; Ozaki K; Suyama H; Yamamoto S; Morimatsu M; Mai LQ; Yamashiro T; Ito T; Otsuki K; Ono E
J Gen Virol; 2016 Sep; 97(9):2104-2116. PubMed ID: 27260213
[TBL] [Abstract][Full Text] [Related]
14. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
[TBL] [Abstract][Full Text] [Related]
15. [Monoclonal antibodies to highly pathogenic avian influenza A(H5N1) strain isolated in the Russian Federation: development and properties].
Kushch AA; Klimova RR; Masalova OV; Fedorova NE; Botikov AG; Fediakina IT; Burtseva EI; Isaeva EI; Deriabin PG; L'vov DK
Vopr Virusol; 2008; 53(5):9-14. PubMed ID: 19069786
[TBL] [Abstract][Full Text] [Related]
16. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.
Chen Y; Qin K; Wu WL; Li G; Zhang J; Du H; Ng MH; Shih JW; Peiris JS; Guan Y; Chen H; Xia N
J Infect Dis; 2009 Jan; 199(1):49-58. PubMed ID: 19032063
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cross-clade monoclonal antibodies against H5N1 highly pathogenic avian influenza virus and their application to the antigenic analysis of diverse H5 subtype viruses.
Gronsang D; Bui AN; Trinh DQ; Bui VN; Nguyen KV; Can MX; Omatsu T; Mizutani T; Nagai M; Katayama Y; Thampaisarn R; Ogawa H; Imai K
Arch Virol; 2017 Aug; 162(8):2257-2269. PubMed ID: 28405766
[TBL] [Abstract][Full Text] [Related]
18. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses.
Sun L; Lu X; Li C; Wang M; Liu Q; Li Z; Hu X; Li J; Liu F; Li Q; Belser JA; Hancock K; Shu Y; Katz JM; Liang M; Li D
PLoS One; 2009; 4(5):e5476. PubMed ID: 19421326
[TBL] [Abstract][Full Text] [Related]
19.
Sutton TC; Lamirande EW; Bock KW; Moore IN; Koudstaal W; Rehman M; Weverling GJ; Goudsmit J; Subbarao K
J Virol; 2017 Dec; 91(24):. PubMed ID: 29046448
[TBL] [Abstract][Full Text] [Related]
20. Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1.
Ascione A; Capecchi B; Campitelli L; Imperiale V; Flego M; Zamboni S; Gellini M; Alberini I; Pittiglio E; Donatelli I; Temperton NJ; Cianfriglia M
Antiviral Res; 2009 Sep; 83(3):238-44. PubMed ID: 19481117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
